Chudecka-Głaz Anita, Rzepka-Górska Izabella
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
Contemp Oncol (Pozn). 2012;16(6):520-5. doi: 10.5114/wo.2012.32485. Epub 2013 Jan 4.
The CD30L ligand is a membrane-associated glycoprotein expressed by activated CD4(+)Th cells, macrophages, dendritic cells, and B lymphocytes. It binds to the CD30 receptor carried on activated and helper Th cells, inducing the immune response and apoptosis. The aim of this retrospective study was to determine the level of sCD30L in the serum of patients at diagnosis of ovarian cancer and at relapse and to assess the potential association of this ligand with selected clinico-pathologic factors.
We studied 69 patients with ovarian cancer allocated to two groups: A - ovarian cancer at diagnosis, B - relapse of ovarian cancer and active growth of the tumor.
We found high levels of sCD30L in ovarian cancer patients. Levels at relapse (21.48 ng/ml) were significantly higher than at diagnosis (11.81 ng/ml). Poor response to first-line chemotherapy was accompanied by higher levels of sCD30L and by several other findings: resistance to platinum analogs was common, neoadjuvant chemotherapy was needed, relapse and death during two-year follow-up were frequent.
Our present study might initially suggest that elevated concentration of sCD30L can be an important finding prognosticating a poor prognosis and is associated with platinum resistant and refractory cases of ovarian cancer. However, studies are needed on larger groups of patients.
CD30L配体是一种与膜相关的糖蛋白，由活化的CD4(+)Th细胞、巨噬细胞、树突状细胞和B淋巴细胞表达。它与活化的辅助性Th细胞上携带的CD30受体结合，诱导免疫反应和细胞凋亡。这项回顾性研究的目的是确定卵巢癌患者诊断时及复发时血清中sCD30L的水平，并评估该配体与选定的临床病理因素之间的潜在关联。
我们研究了69例卵巢癌患者，分为两组：A组 - 诊断时的卵巢癌，B组 - 卵巢癌复发且肿瘤活跃生长。
我们发现卵巢癌患者血清中sCD30L水平较高。复发时的水平（21.48 ng/ml）显著高于诊断时（11.81 ng/ml）。一线化疗反应不佳伴随着sCD30L水平升高以及其他一些情况：对铂类类似物耐药很常见，需要进行新辅助化疗，两年随访期间复发和死亡频繁。
我们目前的研究初步表明，sCD30L浓度升高可能是预测预后不良的一项重要发现，并且与卵巢癌的铂耐药和难治性病例有关。然而，需要对更大规模的患者群体进行研究。
